Author

I. Oehme

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Research Focus:differential expression· 3 Research Focus:drug response / drug discovery· 3 Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

F. Cidre-Aranaz· 4 shared A. Banito· 3 shared H. Peterziel· 3 shared R. Imle· 3 shared T. G. P. Gruenewald· 3 shared A. K. Ceranski· 2 shared C. M. Funk· 2 shared E. Vinca· 2 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

F. Cidre-Aranaz

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Glutaredoxin 3 (GLRX3) confers a fusion oncogene-dependent vulnerability to Ewing sarcoma

E. Vinca, A. C. Ehlers, A. Ritter, D. Obermeier, C. M. Funk, F. H. Geyer, M. Schmucker, J. Li, M. Zimmermann, A. K. Ceranski, F. Fuchslocher, C. Mertens, R. Qiu, M. M. Muckenthaler, A. Dahlhaus, , S. Ohmura

This study identifies GLRX3 as a vulnerability in Ewing sarcoma driven by EWSR1::FLI1 fusion oncoproteins, showing its role in oxidative stress and iron homeostasis and potential therapeutic targeting.

bioRxiv · Apr 24, 2024 · PreprintCancer Biology

Somatic gene delivery for flexible in vivo modeling of high-risk sarcoma

R. Imle, D. Blosel, F. Kommoss, E. Zhao, R. Autry, C. Blume, D. Lupar, L. Schmitt, C. Winter, L. Wagner, S. Placke, M. von Eicke, M. Hertwig, H. Peterziel, I. Oehme, , A. Banito

This paper develops a mouse model for high-risk sarcoma by delivering genetic lesions via electroporation, generating multiple sarcoma types and validating their molecular and therapeutic relevance.

bioRxiv · Jan 30, 2024 · PreprintCancer Biology

Genomic and phenotypic stability of fusion-driven pediatric Ewing sarcoma cell lines

M. Kasan, J. Siebenlist, M. Sill, R. Oellinger, E. de Alava, D. Surdez, U. Dirksen, I. Oehme, K. Scotlandi, O. Delattre, M. Mueller-Nurasyid, R. Rad, K. Strauch, T. G. P. Gruenewald, F. Cidre-Aranaz

This study compares genomic and phenotypic stability of pediatric Ewing sarcoma cell lines to adult carcinoma cell lines over 12 months of culture.

bioRxiv · Nov 20, 2023 · PreprintCell Biology

Chromosome 8 gain drives cancer progression by hijacking the translation factor 4E-BP1 sensitizing for targeted CDK4/6 inhibition

C. M. Funk, A. Ehlers, M. F. Orth, K. Aljakouch, J. Li, T. L. B. Hoelting, R. Will, A. K. Ceranski, F. Willis, E. Vinca, S. Ohmura, R. Imle, J. Siebenlist, A. Yershova, M. M. L. Knott, , J. Musa

This study identifies chr8 gains and 4E-BP1 expression as prognostic markers in Ewing sarcoma, showing they drive cancer progression by promoting proliferation and sensitizing to CDK4/6 inhibitors.

bioRxiv · Dec 11, 2022 · PreprintCancer Biology